Overview

Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty

Status:
Completed
Trial end date:
2020-01-09
Target enrollment:
0
Participant gender:
All
Summary
Tranexamic acid an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin and many studies confirms its effectiveness in decreasing blood loss. The aim of this study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid in adult patients undergoing unilateral total knee replacement.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Centre Hospitalier de Montauban
Treatments:
Tranexamic Acid
Criteria
Inclusion Criteria:

- Adult patients undergoing unilateral total knee replacement

Exclusion Criteria:

- Absence of consent

- Tranexamic acid allergy

- Coagulopathy (preoperative platelet count <150,000 / mm3, INR [international
normalized ratio]> 1.4, or prolonged partial thromboplastin time> 1.4 times normal),

- History of arterial or venous thromboembolic disease (cerebrovascular accident, deep
vein thrombosis or pulmonary thromboembolism),

- Hematological disorder (a hematopoietic, hemorrhagic or thrombogenic disease),

- Retinopathy (severe limitation of the field of vision and / or color distortion),

- Refusal to receive blood products

- Pregnancy

- History of convulsions

- Participation in another clinical trial.